{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:04:44Z","timestamp":1784250284254,"version":"3.55.0"},"reference-count":58,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background\/Objectives: Ulcerative colitis (UC) is a part of inflammatory bowel disease (IBD) and it is characterized by colonic-mucosal chronic inflammation with intermittent clinical activity. Personalized medicine is becoming more and more a relevant method of approach in this field, and the identification of potential concerns in a single patient may contribute to the improvement of the clinical approach. Mesalamine represents the cornerstone of therapy for mild\u2013moderate disease forms, but non-adherence to medical therapy represents a critical health problem, although it is underestimated by many physicians, with evident consequences in terms of disease-related complications. The aim of the present study is to evaluate the magnitude of non-adherence to oral mesalamine in UC patients performing a systematic review and meta-analysis of literature. Methods: A literature search in PubMed and Cochrane databases was performed for studies reporting the non-adherence rate to oral mesalamine in adult UC patients, and eligible studies have been selected for evaluation. The type of study (trial vs. observational), geographic area, sample size, method of adherence assessment, and non-adherence rate were considered. Results: From a total of 464 articles, 34 studies were included in the meta-analysis after selection. Sixteen studies (47%) are observational, and eighteen (53%) are clinical trials. A total of 12\/34 (35%) studies are from North America, 14\/34 (41%) from Europe, 4\/34 (12%) from Asia, with 4\/34 (12%) from mixed areas of the world. The mean non-adherence rate was 32%, but with a consistent variability among the studies. In particular, the non-adherence rate was significantly higher in observational studies vs. clinical trials (47 vs. 20%, p &lt; 0.001), and in North American vs. European and Asian studies (54 vs. 23 vs. 4%, respectively, p &lt; 0.001). Conclusions: The non-adherence rate to oral mesalamine is variably reported in the literature due to the inhomogeneity of available studies, but it represents a consistent problem, often neglected, that deserves future research. A personalized approach by a physician to a single patient can improve the effectiveness of medical therapy and the management of UC patients.<\/jats:p>","DOI":"10.3390\/jpm15040123","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T04:48:18Z","timestamp":1742791698000},"page":"123","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Non-Adherence Rate to Oral Mesalamine in Ulcerative Colitis Patients: A Systematic Review with Meta-Analysis"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9985-7490","authenticated-orcid":false,"given":"Cristiano","family":"Pagnini","sequence":"first","affiliation":[{"name":"Azienda Ospedaliera S. Giovanni Addolorata, 00184 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Antonelli","sequence":"additional","affiliation":[{"name":"Ospedale Santa Maria della Misericordia, 06129 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Scrivo","sequence":"additional","affiliation":[{"name":"Ospedale \u201cARNAS Civico\u2014Di Cristina\u2014Benfratelli\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cappello","sequence":"additional","affiliation":[{"name":"Policlinico \u201cP Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Soncini","sequence":"additional","affiliation":[{"name":"Ospedale A. Manzoni ASST, 23900 Lecco, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Vassallo","sequence":"additional","affiliation":[{"name":"Ospedale Buccheri La Ferla, 90123 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giammarco","family":"Mocci","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera \u201cG. Brotzu\u201d, 09134 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carla","family":"Di Paolo","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera S. Giovanni Addolorata, 00184 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of AIGO IBD Commission","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"ref_1","unstructured":"Sabat\u00e9, E. (2003). Adherence to Long-Term Therapies: Evidence for Action, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Religioni, U., Barrios-Rodr\u00edguez, R., Requena, P., Borowska, M., and Ostrowski, J. (2025). Enhancing Therapy Adherence: Impact on Clinical Outcomes, Healthcare Costs, and Patient Quality of Life. Medicina, 61.","DOI":"10.3390\/medicina61010153"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2023.07.008","article-title":"The role of adherence in patients with chronic diseases","volume":"119","author":"Burnier","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1891\/0739-6686.18.1.48","article-title":"Adherence in chronic disease","volume":"18","author":"Erlen","year":"2000","journal-title":"Annu. Rev. Nurs. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2147\/PPA.S496707","article-title":"Exploring the Perceptions and Self-Perceptions of Therapeutic Adherence in Older Adults with Chronic Conditions: A Scoping Review","volume":"19","author":"Figueiredo","year":"2025","journal-title":"Patient Prefer. Adherence"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Honap","year":"2023","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2023.15389","article-title":"Ulcerative Colitis in Adults: A Review","volume":"330","author":"Gros","year":"2023","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative colitis","volume":"380","author":"Ordas","year":"2012","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/17474124.2024.2397650","article-title":"Practical management of mild-to-moderate ulcerative colitis: An international expert consensus","volume":"18","author":"Magro","year":"2024","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1136\/gutjnl-2022-328221","article-title":"Holistic healthcare in inflammatory bowel disease: Time for patient-centric approaches?","volume":"72","author":"Sudhakar","year":"2023","journal-title":"Gut"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/14712598.2019.1666101","article-title":"Modern use of 5-aminosalicylic acid compounds for ulcerative colitis","volume":"20","author":"Roda","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Mitra, D., Hodgkins, P., Yen, L., Davis, K.L., and Cohen, R.D. (2012). Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis. BMC Gastroenterol., 12.","DOI":"10.1186\/1471-230X-12-132"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9343(02)01383-9","article-title":"Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis","volume":"114","author":"Kane","year":"2003","journal-title":"Am. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2147\/PPA.S127039","article-title":"Adherence in ulcerative colitis: An overview","volume":"11","author":"Testa","year":"2017","journal-title":"Patient Prefer. Adherence"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1046\/j.1365-2036.2002.01370.x","article-title":"Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: A cross-sectional survey","volume":"16","author":"Rubin","year":"2002","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S1542-3565(03)70032-9","article-title":"A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis","volume":"1","author":"Kane","year":"2003","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.5217\/ir.2018.00064","article-title":"Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: A prospective, multicenter, randomized study","volume":"17","author":"Park","year":"2019","journal-title":"Intest. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.cgh.2009.04.004","article-title":"Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis","volume":"7","author":"Dignass","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2147\/PPA.S3698","article-title":"Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial","volume":"2","author":"Kane","year":"2008","journal-title":"Patient Prefer. Adherence"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/ibd.21938","article-title":"One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis","volume":"18","author":"Hawthorne","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2036.2010.04537.x","article-title":"Randomised clinical trial: A comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis","volume":"33","author":"Kruis","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/gut.2007.138248","article-title":"Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis","volume":"57","author":"Kamm","year":"2008","journal-title":"Gut"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1365-2036.2009.04117.x","article-title":"Clinical trial: Ulcerative colitis maintenance treatment with 5-ASA: A 1-year, randomized multicentre study comparing MMX with Asacol","volume":"30","author":"Prantera","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1093\/ibd\/izaa024","article-title":"Use of an iPhone Application to Increase Adherence in Patients With Ulcerative Colitis in Remission: A Randomized Controlled Trial","volume":"26","author":"Ley","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00384-019-03271-9","article-title":"Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system","volume":"34","author":"Ballester","year":"2019","journal-title":"Int. J. Color. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.5217\/ir.2018.00078","article-title":"Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients","volume":"17","author":"Yagisawa","year":"2019","journal-title":"Intest. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/00365521.2018.1451915","article-title":"Adherence, risk factors of non-adherence and patient\u2019s preferred treatment strategy of mesalazine in ulcerative colitis: Multicentric observational study","volume":"53","author":"Keil","year":"2018","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1177\/2050640617703842","article-title":"Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: A double-blind, multicentre, randomised trial","volume":"6","author":"Dignass","year":"2018","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1093\/ecco-jcc\/jjx062","article-title":"Patient Education in a 14-month Randomised Trial Fails to Improve Adherence in Ulcerative Colitis: Influence of Demographic and Clinical Parameters on Non-adherence","volume":"11","author":"Nikolaus","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/MIB.0000000000001065","article-title":"2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial","volume":"23","author":"Suzuki","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_33","first-page":"114","article-title":"What is the real-life maintenance mesalazine dose in ulcerative colitis?","volume":"109","author":"Algaba","year":"2017","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/ibd.21841","article-title":"Strategies in maintenance for patients receiving long-term therapy (SIMPLE): A study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis","volume":"18","author":"Kane","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/j.1365-2036.2009.04152.x","article-title":"An investigation of medication adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis, using self-report and urinary drug excretion measurements","volume":"30","author":"Moshkovska","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1007\/s10620-007-9968-0","article-title":"Medication non-adherence is associated with increased medical health care costs","volume":"53","author":"Kane","year":"2008","journal-title":"Dig. Dis. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1572-0241.2001.04683.x","article-title":"Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis","volume":"96","author":"Kane","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1097\/MIB.0000000000000199","article-title":"eHealth: Individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis","volume":"20","author":"Pedersen","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/01.MIB.0000437500.60546.2a","article-title":"Electronic monitoring of medication adherence in a 1-year clinical study of 2 dosing regimens of mesalazine for adults in remission with ulcerative colitis","volume":"20","author":"Gillespie","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/apt.12013","article-title":"Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: Nationwide 10-year retrospective cohort from the veterans affairs healthcare system","volume":"36","author":"Khan","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Lachaine, J., Yen, L., Beauchemin, C., and Hodgkins, P. (2013). Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: Analyses with the RAMQ database. BMC Gastroenterol., 13.","DOI":"10.1186\/1471-230X-13-23"},{"key":"ref_42","first-page":"701","article-title":"Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis","volume":"18","author":"Yen","year":"2012","journal-title":"J. Manag. Care Pharm."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.crohns.2012.07.027","article-title":"National differences in ulcerative colitis experience and management among patients from five European countries and Canada: An online survey","volume":"7","author":"Schreiber","year":"2013","journal-title":"J. Crohns Colitis"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/11595390-000000000-00000","article-title":"Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: A discrete-choice experiment","volume":"5","author":"Hodgkins","year":"2012","journal-title":"Patient"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1007\/s10620-011-1877-6","article-title":"Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: Results from a large pharmacy prescriptions database","volume":"56","author":"Kane","year":"2011","journal-title":"Dig. Dis. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/ibd.21570","article-title":"Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: Results from an exploratory randomized controlled trial","volume":"17","author":"Moshkovska","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.crohns.2009.10.002","article-title":"Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis\u2014A prospective study","volume":"4","author":"Moss","year":"2010","journal-title":"J. Crohns Colitis"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1097\/MIB.0b013e318286fa3d","article-title":"Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: A double-blind, double-dummy, randomized multicenter study","volume":"19","author":"Watanabe","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2147\/PPA.S346309","article-title":"Self-Reported Medication Adherence Among Patients with Ulcerative Colitis in Japan and the United Kingdom: A Secondary Analysis for Cross-Cultural Comparison","volume":"16","author":"Kawakami","year":"2022","journal-title":"Patient Prefer. Adherence"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4292\/wjgpt.v8.i1.67","article-title":"Current practice and clinicians\u2019 perception of medication non-adherence in patients with inflammatory bowel disease: A survey of 98 clinicians","volume":"8","author":"Soobraty","year":"2017","journal-title":"World, J. Gastrointest. Pharmacol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"102915","DOI":"10.1016\/j.eclinm.2024.102915","article-title":"Real-world data: Bridging the gap between clinical trials and practice","volume":"78","author":"Wilson","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref_52","first-page":"E32","article-title":"Peer reviewed: Relationship between adherence to antihypertensive medication regimen and out-of-pocket costs among people aged 35 to 64 with employer-sponsored health insurance","volume":"16","author":"Roy","year":"2019","journal-title":"Prev. Chronic Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/QAI.0b013e31825db0bd","article-title":"Racial\/Ethnic disparities in ART adherence in the United States: Findings from the MACH14 study","volume":"60","author":"Simoni","year":"2012","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_54","first-page":"117","article-title":"An overview of the common methods used to measure treatment adherence","volume":"92","author":"Anghel","year":"2019","journal-title":"Med. Pharm. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Mu\u00f1oz, A.M., Victoria-Montesinos, D., Cerd\u00e1, B., Ballester, P., de Velasco, E.M., and Zafrilla, P. (2023). Self-Reported Medication Adherence Measured with Morisky Scales in Rare Disease Patients: A Systematic Review and Meta-Analysis. Healthcare, 11.","DOI":"10.3390\/healthcare11111609"},{"key":"ref_56","first-page":"542","article-title":"Assessing medication adherence in inflammatory bowel diseases. A comparison between a self-administered scale and a pharmacy refill index","volume":"109","author":"Sanroman","year":"2017","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2147\/CEG.S237653","article-title":"Patient Preference and Adherence to Aminosalicylates for the Treatment of Ulcerative Colitis","volume":"14","author":"Tripathi","year":"2021","journal-title":"Clin. Exp. Gastroenterol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2036.2007.03555.x","article-title":"Risk factors for non-adherence to medication in inflammatory bowel disease patients","volume":"27","author":"Bertomoro","year":"2008","journal-title":"Aliment. Pharmacol. Ther."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/4\/123\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:59:00Z","timestamp":1760029140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/4\/123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":58,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["jpm15040123"],"URL":"https:\/\/doi.org\/10.3390\/jpm15040123","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]}}}